DADC
CTMX icon

D.A. Davidson & Co’s CytomX Therapeutics CTMX Stock Holding History

D.A. Davidson & Co’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-10,030
Closed -$113K – 1010
2019
Q2 		$113K Buy
+10,030
New +$105K ﹤0.01% 948
2017
Q3 		– Sell
-2,500
Closed -$38K – 1262
2017
Q2 		$38K Hold
2,500
– – ﹤0.01% 1620
2017
Q1 		$43K Buy
+2,500
New +$32.9K ﹤0.01% 1570

Other funds holding CTMX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

D.A. Davidson & Co's CTMX Position: Q3 2019 in Review

D.A. Davidson & Co sold out of CytomX Therapeutics (CTMX) in Q3 2019, closing a stake of 10,030 shares — an estimated $113K sold.

D.A. Davidson & Co first reported a position in CTMX in Q1 2017 and held it in 3 quarters. The position peaked at $113K in Q2 2019. 113 funds tracked by Wall St. Rank hold CTMX as of Q3 2019.

  • D.A. Davidson & Co reported no remaining CytomX Therapeutics position as of Q3 2019 after selling out during the quarter.
  • D.A. Davidson & Co sold 10,030 CytomX Therapeutics shares in Q3 2019, an estimated $113K.
  • D.A. Davidson & Co first reported a position in CytomX Therapeutics in Q1 2017 and held it in 3 quarters.
  • D.A. Davidson & Co's CytomX Therapeutics position peaked at $113K in Q2 2019.
  • 113 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q3 2019.

Based on D.A. Davidson & Co's 13F filing for Q3 2019, filed 5 Nov 2019.